Polymer Micropatches as B-Cell Engagers

Area of Science:

• Immunology
• Cell Therapy
• Biotechnology

Background:

• B cells are underutilized in adoptive cell therapy despite their antigen-presenting capabilities.
• Current methods for B cell activation in vivo are limited by difficulties in achieving sufficient concentrations of stimulating biologics.
• Dendritic cells (DCs) have shown limited efficacy as antigen-presenting cells (APCs) in clinical settings.

Purpose of the Study:

• To investigate the potential of Micropatches as Cell Engagers (MACE) to enhance B cell function for adoptive cell therapy.
• To evaluate MACE-mediated B cell activation, antigen presentation, and in vivo therapeutic efficacy.
• To explore B cells as a viable alternative to DCs for cellular immunotherapy.

Main Methods:

• MACE, polymeric microparticles functionalized with anti-CD40 and anti-IgM, were used to engage B cells.
• B cell activation, costimulatory molecule expression, viability, and antigen presentation to T cells were assessed in vitro.
• MACE-bound B cells were adoptively transferred into a murine tumor model to evaluate in vivo homing and anti-tumor activity.

Main Results:

• MACE stimulation enhanced B cell display of costimulatory molecules, increased viability, and improved antigen presentation in vitro.
• MACE-bound B cells exhibited enhanced T cell chemokine secretion and synergized with soluble IL-4 and anti-CD40.
• Adoptively transferred MACE-bound B cells successfully homed to lymphoid organs and significantly delayed tumor progression in a murine model.

Conclusions:

• MACE technology effectively enhances B cell activation and function, positioning them as potent APCs for adoptive cell therapy.
• MACE-bound B cells demonstrate promising in vivo homing and anti-tumor efficacy, overcoming limitations of traditional B cell therapies.
• This approach offers a novel strategy to harness B cells for cancer immunotherapy and other therapeutic applications.